Dapsone: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 18: | Line 18: | ||
*50mg PO QD | *50mg PO QD | ||
===PCP=== | ===[[Pneumocystis jirovecii pneumonia|PCP]]=== | ||
*Prophylaxis: 100mg/day PO divided QD-bid | *Prophylaxis: 100mg/day PO divided QD-bid | ||
**Off label use | **Off label use | ||
| Line 81: | Line 81: | ||
==References== | ==References== | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] | ||
Latest revision as of 23:51, 20 September 2019
Administration
- Type: Antibiotic
- Dosage Forms: 25,100
- Routes of Administration: Oral
Adult Dosing
Hansen's disease (leprosy)
- paucibacillary: 100mg PO QD x6mo
- Use with rifampin
- multibacillary: 100mg PO QD x12mo
- Use with rifampin, clofazimine
Bullous pemphigoid
- 50mg PO QD
- Use with topical or systemic corticosteroids
Dermatitis herpetiformis
- 50mg PO QD
PCP
- Prophylaxis: 100mg/day PO divided QD-bid
- Off label use
- Treatment: 100mg PO QD x21 days
- Not 1st-line agent; use with trimethoprim
- Off label use
Malaria suppression
- 100mg PO qwk
- Use with pyrimethamine
- Off label use
Toxoplasmosis prophylaxis
- 50mg PO QD
- Off label use
Pediatric Dosing
Special Populations
- Pregnancy Rating: C
- Lactation risk: Probably unsafe
Renal Dosing
- No adjustment
Hepatic Dosing
- Caution advised with hepatic impairment
- CBC qwk x4, qmo x6, then q6mo thereafter
- LFTs at baseline, then periodically
Contraindications
- Allergy to class/drug
- caution if renal or hepatic impairment
- caution if impaired cardiovascular function
Adverse Reactions
Serious
- anemia, hemolytic
- aplastic anemia
- agranulocytosis
- exfoliative dermatitis
- erythema multiforme
- toxic epidermal necrolysis
Common
Pharmacology
- Half-life: 28 hrs
- Metabolism: Liver, CYP450
- Excretion: Urine
